Aeterna Zentaris: Plunges on $4.5 mln direct offering

COSCIENS Biopharma

20/02/2020 14:01

** U.S.-listed shares of Canadian drug developer  AEZS.O 
falls 26.5% to $1 premarket on about $4.5 mln direct offering
    ** Stock among worst pct loser across U.S. exchanges; set
for its worst day in nearly three years
    ** AEZS' direct offering is for the sale of about 3.5 mln
common shares at $1.29/shr
    ** Will also issue unregistered warrants for 2.6 mln common
shares at an exercise price of $1.20/shr    
    ** Offering represents 17.4% of the company's free float 
    ** Up to Wednesday's close, stock fell ~67% in the last 12
months 

 (Reporting by Dania Nadeem in Bengaluru)
 ((Dania.Nadeem@thomsonreuters.com; within U.S. +1 646 223 8780,
outside U.S. +91 80 6182 3463;))